Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_4
3
60%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 4Post-market surveillance
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Other(5)

Detailed Status

unknown5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 43 (60.0%)
N/A1 (20.0%)

Trials by Status

unknown5100%

Recent Activity

0 active trials
Showing 5 of 5
unknownphase_4

Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

NCT05559307
unknownnot_applicable

Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

NCT04813445
unknownphase_4

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

NCT04150835
unknownphase_4

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

NCT02728180
unknownphase_1

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

NCT02367248

Clinical Trials (5)

Showing 5 of 5 trials
NCT05559307Phase 4

Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

Unknown
NCT04813445Not Applicable

Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Unknown
NCT04150835Phase 4

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Unknown
NCT02728180Phase 4

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Unknown
NCT02367248Phase 1

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5